Melanoma Antigens and Antibodies

450 Pages·1982·8.55 MB·English

by  Ronald T. Acton

Melanoma Antigens
and Antibodies
Melanoma Antigens
and Antibodies
Edited by
Ralph A. Reisfeld
Scripps Clinic and Research Foundation
La Jolla, California
and
Soldano Ferrone
Columbia University
New York, New York
PLENUM PRESS. NEW YORK AND LONDON
Library of Congress Cataloging in Publication Data
Main entry under title:
Melanoma antigens and antibodies
Includes bibliographical references and index.
1. Melanoma-Immunological aspects. 2. Tumor antigens. 3. Immunoglobulins.
I. Reisfeld, Ralph A. II. Ferrone, Soldano, 1940- . [DNLM: 1. Melanoma-
Immunology. QZ 200 M517]
RC280.S5M38 616.99'4 82-5288
ISBN-13: 978-1-4684-4081-2 e-ISBN-13: 978-1-4684-4079-9 AACR2
DOl: 10.1007/978-1-4684-4079-9
© 1982 Plenum Press, New York
Softcover reprint of the hardcover 1st edition 1982
A Division of Plenum Publishing Corporation
233 Spring Street, New York, N.Y. 10013
All rights reserved
No part of this book may be reproduced, stored in a retrieval system, or transmitted
in any form or by any means, electronic, mechanical, photocopying, microfilming,
recording, or otherwise, without written permission from the Publisher
Contributors
ROBERTO S. ACCOLLA, Unit of Human Cancer Immunology, Lausanne Branch, Ludwig Institute
for Cancer Research, 1066 Epalinges, Switzerland
RONALD T. ACTON, Departments of Microbiology and Epidemiology, University of Alabama in
Birmingham, Birmingham, Alabama 35294
CHARLES M. BALCH, Departments of Microbiology and Surgery; Cellular Immunobiology Unit,
Comprehensive Cancer Center; Veterans Hospital, University of Alabama in Birmingham,
Birmingham, Alabama 35294
BRUCE O. BARGER, Department of Microbiology and Epidemiology, University of Alabama in Bir
mingham, Birmingham, Alabama 35294
JOSEF BROGGEN, Department of Experimental Dermatology, Universitats-Hautklinik, 4400
Munster, West Germany
BRUCE BUDOWLE, Department of Microbiology, University of Alabama in Birmingham, Birming
ham, Alabama 35294
JEAN-CLAUDE BYSTRYN, Department of Dermatology, New York University School of Medicine,
New York, New York 10016
STEFAN CARREL, Unit of Human Cancer Immunology, Lausanne Branch, Ludwig Institute for
Cancer Research, 1066 Epalinges, Switzerland
RENATO CAVALIERE, Istituto Regina Elena, 00161 Rome, Italy
ALISTAIR J. COCHRAN, Division of Surgical Oncology and Departments of Surgery and Pathology,
UCLA School of Medicine, University of California, Los Angeles, California 90024
PETER B. DENT, Departments of Pediatrics and Pathology, McMaster University; The Ontario
Cancer Treatment & Research Foundation (Hamilton Clinic), Hamilton, Ontario, L8N 3Z5
Canada
SOLDANO FERRONE, Department of Pathology, College of Physicians and Surgeons, Columbia Uni
versity, New York, New York 10032
D. R. GALLOWAY, Department of Molecular Immunology, Scripps Clinic and Research Founda
tion, La Jolla, California 92037
v
VI CONTRIBl'TORS
DOUGLAS M. GERSTEN, Department of Pathology and National Biomedical Research Foundation,
Georgetown University, Washington, D.C. 20007
RODNEY C. P. Go, Department of Epidemiology, University of Alabama in Birmingham, Bir
mingham, Alabama 35294
NICOLE GROSS, Unit of Human Cancer Immunology, Lausanne Branch, Ludwig Institute for Can
cer Research, 1066 Epalinges, Switzerland
RISHAB K. GUPTA, Division of Oncology, Department of Surgery, UCLA School of Medicine,
University of California, Los Angeles, California 90024; and Surgical Service, V.A. Medical
Center, Sepulveda, California 91343
W. J. HALLIDAY, Department of Microbiology, University of Queensland, Brisbane, Australia
4067
INGEGERD HELLSTROM, Division of Tumor Immunology, Fred Hutchinson Cancer Research Cen
ter, Seattle, Washington 98104; Departments of Microbiology/Immunology and Pathology,
University of Washington, Seattle, Washington 98195
KARL ERIK HELLSTROM, Division of Tumor Immunology, Fred Hutchinson Cancer Research Cen
ter, Seattle, Washington 98104; Departments of Microbiology/Immunology and Pathology,
University of Washington, Seattle, Washington 98195
PETER HERSEY, Medical Research Department, Kanematsu Memorial Institute, Sydney Hospital,
Sydney, N.S.W. 2000, Australia
ARIEL HOLLINSHEAD, Division of Hematology and Oncology, Department of Medicine, The
George Washington University Medical Center, Washington, D.C. 20037
KOHZOH IMAI, Department of Molecular Immunology, Scripps Clinic and Research Foundation,
La Jolla, California 92037
YOSHIFUMI ISHII, Department of Developmental Therapeutics, M.D. Anderson Hospital and
Tumor Institute, Houston, Texas 77030
NEIL E. KAY, Department of Pathology, College of Physicians and Surgeons, Columbia University,
New York, New York, 10032
PETER J. KELLEHER, Department of Medicine, National Jewish Hospital and Research Center,
Denver, Colorado 80206
HILARY KOPROWSKI, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania
19104
W. DANIEL KUNDlN, Division of Hematology and Oncology, Department of Medicine, The George
Washington University Medical Center, Washington, D.C. 20037
M. G. LEWIS, Department of Pathology, Stritch School of Medicine, Loyola University, Maywood,
Chicago, Illinois 60153
SHUEN-KuEI LIAO, Departments of Pediatrics and Pathology, McMaster University; The Ontario
Cancer Treatment & Research Foundation (Hamilton Clinic), Hamilton, Ontario, L8N 3Z5
Canada
JEAN-PIERRE MACH, Unit of Human Cancer Immunology, Lausanne Branch, Ludwig Institute
for Cancer Research, 1066 Epalinges, Switzerland
CONTRIBUTORS VII
EGON MACHER, Department of Experimental Dermatology, Universitats-Hautklinik, 4400 Muns
ter, West Germany
JOHN J. MARCHALONIS, Department of Biochemistry, Medical University of South Carolina,
Charleston, South Carolina 29403
GIORA M. MAVLIGIT, Department of Developmental Therapeutics, M. D. Anderson Hospital and
Tumor Institute. Houston, Texas 77030
R. P. MCCABE, Department of Molecular Immunology, Scripps Clinic and Research Foundation,
La Jolla, California 92037
WILLIAM H. MCCARTHY, Melanoma Unit, Department of Surgery, University of Sydney, Sydney
Hospital, Sydney, N.S.W. 2000, Australia
PERCY MINDEN, Department of Medicine, National Jewish Hospital and Research Center, Den
ver, Colorado 80206
KENNETH F. MITCHELL, The Wi star Institute of Anatomy and Biology, Philadelphia, Pennsyl
vania 19104
ALTON C. MORGAN, JR., Department of Molecular Immunology, Scripps Clinic and Research
Foundation, La Jolla, California 92037
DONALD L. MORTON, V. A. Medical Center, Sepulveda, California 91343; and Division of Oncol
ogy, Department of Surgery, UCLA School of Medicine, University of California, Los Ange
les, California 90024
PIER-GIOIU;IO NA I ALI, htitutu Regina Elena, 00161 Rome, Italy
MICHELE A. PELLEGRINO, Department of Pathology, College of Physicians and Surgeons, Colum
bia University, New York, New York, 10032
T. M. PHILLIPS, Department of Medicine, George Washington Medical Center, Washington, D.C.
20037
W. D. Ql'EEN, Department of Medicine, George Washington Medical Center, Washington, D.C.
20037
R. A. REISFELD, Department of Molecular Immunology, Scripps Clinic and Research Foundation,
La Jolla, California 92037
JEFFREY M. ROSEMAN, Department of Epidemiology, University of Alabama in Birmingham, Bir
mingham, Alabama 35294
CHARLES SCOTT, Paul M. Aggeler Memorial Laboratory, Department of Medicine, Children's
Hospital, University of California Medical Center, San Francisco, California 94122
SENG-JAW SOONG, Department of Biostatistics, University of Alabama in Birmingham, Birming
ham, Alabama 35294
CLEMENS SORG, Department of Experimental Dermatology, Universitats-Hautklinik, 4400 Muns
ter, West Germany
LYNN E. SPITLER, Paul M. AggelerMemorial Laboratory, Department of Medicine, Children's
Hospital, University of California Medical Center, San Francisco, California 94122
ZENON STEPLEWSKI, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania
19104
Vlll CONTRIBUTORS
LUDWIG SUTER, Department of Experimental Dermatology, Universitats-Hautklinik, 4400 Muns
ter, West Germany
KEITH TANNER, Division of Hematology and Oncology, Department of Medicine, The George
Washington University Medical Center, Washington, D.C. 20037
DOROTHEA TERBRACK, Department of Experimental Dermatology, Universitats-Hautklinik, 4400
Munster, West Germany
D. M. P. THOMSON, The Montreal General Hospital Research Institute, The Montreal General
Hospital, Quebec, Canada H3G lA4
ARABELLA B. TILDEN, Departments of Microbiology and Surgery; Cellular Immunobiology Unit,
Comprehensive Cancer Center; Veterans Hospital, University of Alabama in Birmingham,
Birmingham, Alabama 35294
FEREYDOUN VAKILZADEH, Department of Experimental Dermatology, Universitats-Hautklinik,
4400 Munster, West Germany
BARRY S. WILSON, Department of Pathology, University of Michigan Medical School, Ann Arbor,
Michigan 48109
LINDA K. WOODS, Surgical Oncology Laboratory, Denver General Hospital, Denver, Colorado
80204
Preface
The ever-expanding research on human cancer has resulted in numerous technical and
conceptual advances during the last few years. Serological, structural, and biological char
acterization of human melanoma constitutes one area of research that has received consid
erable attention from researchers and clinicians and has generated new and exciting infor
mation. In this volume, we have attempted to assemble work on topics that produced some
of the most recent advances. We asked each author to describe and interpret his most cur
rent research and, whenever possible, to compare and contrast it with work of other inves
tigators in the field. We have been careful not to impose our viewpoints except in contri
butions from our own laboratories, since we want to provide the reader with as many
divergent and sometimes opposing viewpoints as feasible. Therefore, we have not been
overly concerned with overlaps in some individual topics. We hope that this volume will
provide the reader with a well-balanced overview of current problems and ideas in a par
ticular area of cancer research.
We wish to express our thanks to all contributors for their timely and very interesting
manuscripts, and we sincerely hope that the reader will enjoy this volume and benefit as
much from it as we did.
R. A. Reisfeld
S. Ferrone
La Jolla
ix
Contents
CHAPTER 1
Immunogenetics of Melanoma
RONALD T. ACTON, CHARLES M. BALCH, BRUCE BUDOWLE, RODNEY C. P. Go,
JEFFREY M. ROSEMAN, SENG-jAW SOONG, AND BRUCE O. BARGER
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2. Genetic Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
3. An Immunogenetic Analysis of Melanoma Patients in Alabama. . . . . . . . . . . . . . . . 10
4. Implications and Future Direction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
CHAPTER 2
Indomethacin, Prostaglandin, and Immune Regulation in Melanoma
CHARLES M. BALCH AND ARABELLA B. TILDEN
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2. Prostaglandin and Indomethacin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3. Helper- and Suppressor-Cell Function in Tumor-Bearing Mice ............... 25
4. Helper- and Suppressor-Cell Function in Cancer Patients ............... _. . . . . 26
5. Mitogen Response in Melanoma Patients and Normal Subjects . . . . . . . . . . . . . . . . 27
6. Effects of Indomethacin on Mitogen Response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
7. Correlation with Clinical Status of Melanoma Patients. . . . . . . . . . . . . . . . . . . . . . . 29
8. Indomethacin Effects on Purified Lymphocytes and Monocytes .. . . . . . . . . . . . . . . 29
9. Are the Indomethacin Effects Related to Prostaglandin? . . . . . . . . . . . . . . . . . . . . . . 30
10. Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
CHAPTER 3
Shedding and Degradation of Cell-Surface Macromolecules and Melanoma
Associated Antigens by Human Melanoma
JEAN-CLAUDE BYSTRYN
1. Introduction ........................................................ . 37
2. Release of Tumor Antigens. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
xi
XII CONTENTS
3. Degradation of Shed Tumor Antigens 44
4. Conclusion .. 49
References 50
CHAPTER 4
Monoclonal Antibodies as a Tool to Detect Melanoma-Associated Antigens
STEFAN CARREL, ROBERTO S. ACCOLLA, JEAN-PIERRE MACH, AND NICOLE GROSS
1. Introduction ............................. . 53
2. Materials and Methods . 54
3. Results .......... . 59
4. Discussion 69
References 71
CHAPTER 5
Tumor-Directed Cellular Immunity in Malignant Melanoma and the Antigens
That Evoke It
J.
ALISTAIR COCHRAN
1. Introduction. ................. . . . . . . . . . . . . . 75
2. Studies Employing the Direct One-Stage Capillary Leukocyte Migration-
Inhibition Technique. . 77
3. Clinical Stage and Tumor-Directed Cellular Immunity 80
4. Tumor-Directed Immunity during Tumor Regression 82
5. Effects of Treatment on Tumor-Directed Immunity 83
6. Correlation of Tumor-Directed Immunity and Histology 86
7. Formalinized Cell Suspensions as "Antigen" in One- and Two-Stage Leukocyte-
Migration Assays. . . . . . . . . . . . . 86
8. Reactions of Melanoma Patients' and Control Donors' Leukocytes with Fetal
Materials . . . . . . . . . . . . . . 88
9. Reactions of Melanoma Patients' and Control Donors' Leukocytes with Materials
from Nevi, Perimelanomatous Skin, Skin Involved by Lentigo Maligna, and
Normal Skin 89
to. Indirect L,fukocyte-Migration Assays. 90
11. Concordance of Indirect and Direct Leukocyte-Migration Assays. 95
12. Mechanism of Tumor-Cell-Induced Inhibition of Human Leukocyte Migration. 95
13. Tissue-Cultured Lymphoblastoid Cells as Indicators of Lymphokine Generation 95
References 97
CHAPTER 6
Heterogeneity of Human Melanoma-Associated Antigens Revealed by
Alloantisera and Xenoantisera
PETER B. DENT AND SHUEN-KuEI LIAO
1. Introduction . . . ......................................... . 101
2. Methodological Considerations ................... . 102
3. Human Antibodies to Melanoma 103
4. Nonhuman Primate Antibodies to Melanoma 106
5. Rabbit Antibodies to Melanoma. 109
6. Monoclonal Antibodies to Melanoma. Ito